Financial Times FT.com

Resources

Principal content

Triputra Group welcomes strategic partners to back aggressive growth, founder says

Indonesian conglomerate targets revenue boost with help from strategic partners by Mergermarket

Chronic disease conditions could attract pharma-accountable care organization collaboration

Data mining, patient treatment patterns may be the best avenues for pharma to explore by BioPharm Insight

No disclosure of leniency documents in EU private damages litigation – draft directive

The long-awaited draft EU legislative proposal on private damages actions, expected in the next several weeks, stipulates that leniency applications in the antitrust authority’s files should not be disclosed for the purposes of damages actions by PaRR

CIRCOR said to attract interest from trade buyer

Graco, Parker Hannifin seen as potential suitors by Dealreporter

NZ Finance Minister bullish on privatization schedule after Mighty River sale

The government intends to take advantage of a “window of opportunity” to list three remaining energy companies by Dealreporter

CDC mulls new strategies to improve HCV testing required to link patients to care

New study finds only 51% of patients receive all required testing by BioPharm Insight

Brazil’s CADE ramping up for Google investigation while Buscape flanks search giant with civil suit appeal

Brazilian antitrust regulator laying groundwork for Google investigation by PaRR

Switzerland and EU antitrust cooperation agreement set for 17 May signing

The first-of-its-kind ‘second generation’ antitrust cooperation agreement between EU and Switzerland is set to be signed on 17 May in Brussels, but it is not expected to come into force until 2014 and is unlikely to have a major impact on on-going antitrust investigations by PaRR

Europe regulators not yet on board with adult ADHD due to concerns regarding diagnosis methods

Tide could be turning as companies continue to eye this space and experts point to healthcare cost savings by BioPharm Insight

Russian Supreme Court head expects new antimonopoly guidelines for courts soon

In an exclusive interview with PaRR, the head of Russia’s Supreme Commercial Court (VAS) analyses VAS competition cases, outlines new challenges faced by Russian companies and reveals VAS plans by PaRR

EP Energy selling US natural gas assets via Evercore and RBC

Still figuring out China

Unilever to divest Wish-Bone via Goldman Sachs

Coal emerges as Cinderella at China’s energy ball

PepsiCo said to shun sugary Mondelez

German drug rebate future at centre of debate as industry versus payer battle intensifies

J&J’s Remicade six-month patent extension to stave off Celltrion biosimilar threat in major EU markets

Customs Union to have four antitrust agencies by 2014, says Deputy FAS Head

Celltrion slides to third in race for Roche rituximab biosimilar with planned 2H13 Phase III trial start

Telecom Italia/Hutchison 3 Italia four-to-three deal to face EC scrutiny

Peterson Farms up for sale via Quarton Partners

Imminent ThyssenKrupp rights issue unlikely but may provide long term options

UK’s value-based pricing pilot schemes seen as path forward to preserve political promises

How Medco won antitrust approval for a deal Wall Street considered doomed

Alcatel Lucent nominal value cut hints at future capital raise – sector bankers

Mid-sized Korean law firms seek Myanmar presence to tap energy potential - Analysis

Buyouts face tender delays under new SEC mandate

More entries and fewer exits in Latin America private equity - Analysis

Fiat still targeting VEBA agreement as Chrysler IPO parade kicks off

More REITs expected following Mapletree Greater China Commercial Trust’s strong debut

UK value-based pricing will struggle to materialise as year-end deadline approaches

New Mexico Gas Company on the block

Ralls CFIUS block alters Sany’s future investment strategy in US

Chiltern in talks to get new majority investor; hires Jefferies – sources

Lundbeck and Otsuka’s once-monthly schizophrenia drug advantageous though late market entry could hinder uptake

HIV drugs to be uniquely shielded from generic pricing pressure in public payer scheme

Novartis has fair claim to challenge German drug pricing law though weak case to protect diabetes drugs

Asia investment grade bond volume looking flat for the year

Endo’s law suit against Impax for crush-proof Opana unlikely to reach settlement before May FDA ruling

Japan private equity landscape expected to see deal upswing in 2013

Best Buy buyout talks quiet

Crisis hit platinum sector ripe for consolidation amid restructuring

Active Biotech/Ipsen’s prostate cancer drug mechanism clouds opinion of improving overall survival

National Grid’s battle with Ofgem reflects political focus on energy

EU TrendMonitor – Almunia legacy to take shape with major cases wrapping up and important legislative initiatives imminent

Supply chain concerns rejected in CFIUS review of A123

BRICS Russia TrendMonitor - Russia’s FAS to take tough 2013 line on cartels, strategic asset protection

Alibaba to meet advisors after holiday on group IPO, sources say

Lilly/Boehringer remain coy on insulin glargine’s EU, FDA regulatory strategies

Addition of concept of “collective dominance” to Indian Competition Act will strengthen country’s antitrust regulator